Clinical Trial Update: A Phase 1/1b Study of IAM1363 in HER2 Cancers [Phase 1]

View source ↗

Summary

IAM1363 is being studied in a Phase 1/1b trial for HER2-related cancers, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Breast Cancer
• Colorectal Cancer
• Esophageal Cancer
• Gastric Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• IAM1363

Snippet

Sponsor: Iambic Therapeutics, Inc | Conditions: HER2 Mutation-Related Tumors, HER2 | Phase 1 | Status: RECRUITING